Ernexa Therapeutics Inc.
- Market Cap (Float-Adj) (Float-adjusted market cap computed by the low-float screener — matches the screener row. May differ from the standard cap (price × all shares outstanding) reported elsewhere.)
- $3.9M
- Price
- $2.39
- % Change (Daily % change from the live per-ticker quote feed.)
- +6.94%
- Volume
- 662.9K
About
Ernexa Therapeutics Inc. is a biotechnology firm currently in its preclinical development phase, specializing in the creation of therapeutic interventions using induced mesenchymal stem cells (iMSCs). The company's primary focus lies in addressing solid tumor cancers and a range of autoimmune diseases. Its flagship candidate, ERNA-101, is an allogeneic iMSC designed to release pro-inflammatory cytokines, namely IL-7 and IL-15, intended for the treatment of ovarian cancer. Additionally, Ernexa is developing ERNA-102, an iMSC product engineered to secrete the anti-inflammatory cytokine IL-10, aimed at managing rheumatoid arthritis. The company has a licensing arrangement in place with Factor Bioscience Limited. Established in 2018, this Cambridge, Massachusetts-based entity operated as Eterna Therapeutics Inc. until its rebranding to Ernexa Therapeutics in March 2025.
Quick stats
Shares outstanding1.6M
Computed float966.7K
Float / shares59.2%
Cash runway (months)2.7
Key info
SectorHealthcare
IndustryBiotechnology
CIK (Central Index Key — the unique ID the SEC assigns to every filer. Use it to look up the company's filings on EDGAR.)0000748592
Websitehttps://www.ernexatx.com
AI Summary
AI-generated1/25
minorbullishclinical trial
Ernexa Therapeutics’ ERNA-101 Selected for Flash Talk Presentation at Nature Conferences’ Next-Generation Cancer Therapeutics Meeting Co-Hosted by MD Anderson Cancer Center
Ernexa Therapeutics announced that new preclinical data for its lead oncology program ERNA-101 were selected for a Flash Talk at the Next-Generation Cancer Therapeutics meeting co-hosted by Nature Conferences and MD Anderson Cancer Center, October 6-8, 2026 in Houston.
In preclinical models of high-grade serous ovarian cancer, ERNA-101 promoted immune cell recruitment, drove significant tumor regression and enhanced survival, and combined with PD-1 blockade achieved complete tumor control and durable responses in the majority of treated animals.
The company plans to submit an IND to the FDA in Q4 2026 and expects first clinical data from a first-in-human study in platinum-resistant ovarian cancer in Q4 2027; preclinical spending on ERNA-201 has been paused to concentrate resources on ERNA-101.
Red flags
- still preclinical-stage; IND not yet submitted
- preclinical development of ERNA-201 paused, narrowing the pipeline